IP Library › Granted Patent US 12,291,530
Granted Patent B1
US 12,291,530 · App. 18/885,065 · Granted May 6, 2025

GLP-1R agonist and therapeutic method thereof

Inventors: Bin Liang (Hong Kong, CN); Jinzi Jason Wu (Hong Kong, CN); Bailing Yang (Hong Kong, CN)
Assignee: Ascletis Pharma (China) Co., Limited
C07D471/04A61K31/437A61K31/4985A61K31/519A61K31/5415A61K31/675C07D519/00C07F9/6561
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,291,530
App. No.
18/885,065
Granted
May 6, 2025
Kind
B1
Abstract

The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Claims (13)

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

2. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of a sodium salt, a calcium salt, a potassium salt, a magnesium salt and a lithium salt.

3. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of:

4. The compound, or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of:

5. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

6. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

7. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

8. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

9. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

10. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

11. A compound, selected from the group consisting of:

12. A pharmaceutical composition, comprising the compound, or the pharmaceutically acceptable salt thereof of claim 1 , and a pharmaceutically acceptable excipient.

13. A pharmaceutical composition, comprising the compound of claim 11 , and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2025
From: LIANG, BIN; WU, JINZI JASON; YANG, BAILING
To: ASCLETIS PHARMA (CHINA) CO., LIMITED
Reel/Frame 069998/0268 →
Priority Claims (8)
CN 202311582240.2 · Nov 24, 2023 · national
CN 202311686034.6 · Dec 8, 2023 · national
CN 202410142451.2 · Jan 31, 2024 · national
CN 202410202078.5 · Feb 22, 2024 · national
CN 202410398964.X · Apr 2, 2024 · national
CN 202410584679.7 · May 11, 2024 · national
CN 202410906296.7 · Jul 5, 2024 · national
CN 202411237013.0 · Sep 4, 2024 · national
Continuity (2)
Provisional Application 63673461 · Jul 19, 2024
Provisional Application 63603854 · Nov 29, 2023
References Cited (283)
US 6482844B1 · He et al. · 2002 [cited by applicant]
US 9120813B2 · Mjalli et al. · 2015 [cited by applicant]
US 9150482B2 · Wu · 2015 [cited by applicant]
US 9198901B2 · Almariego et al. · 2015 [cited by applicant]
US 10392357B2 · Chein et al. · 2019 [cited by applicant]
US 20110064806A1 · Polisetti et al. · 2011 [cited by applicant]
US 20190225604A1 · Yoshino · 2019 [cited by examiner]
US 20240199589A1 · Armstrong et al. · 2024 [cited by applicant]
CN 101195612B · 2012 [cited by applicant]
CN 102378574B · 2013 [cited by applicant]
CN 104080767A · 2014 [cited by applicant]
CN 103694195B · 2016 [cited by applicant]
CN 102946882B · 2016 [cited by applicant]
CN 106588749A · 2017 [cited by applicant]
CN 105622687B · 2018 [cited by applicant]
CN 109867630A · 2019 [cited by applicant]
CN 112451515A · 2021 [cited by applicant]
CN 111548311B · 2021 [cited by applicant]
CN 107074820B · 2021 [cited by applicant]
CN 113480534B · 2022 [cited by applicant]
CN 114478497A · 2022 [cited by applicant]
CN 114478497B · 2022 [cited by applicant]
CN 114591296A · 2022 [cited by applicant]
CN 114634510A · 2022 [cited by applicant]
CN 114716423A · 2022 [cited by applicant]
CN 114763352A · 2022 [cited by applicant]
CN 114790160A · 2022 [cited by applicant]
CN 114805336A · 2022 [cited by applicant]
CN 114907351A · 2022 [cited by applicant]
CN 115279750A · 2022 [cited by applicant]
CN 115286550A · 2022 [cited by applicant]
CN 115315426A · 2022 [cited by applicant]
CN 115697968B · 2022 [cited by applicant]
CN 115536638A · 2022 [cited by applicant]
CN 115594669A · 2023 [cited by applicant]
CN 115667219A · 2023 [cited by applicant]
CN 115667268B · 2023 [cited by applicant]
CN 115703766A · 2023 [cited by applicant]
CN 115703792A · 2023 [cited by applicant]
CN 113831337B · 2023 [cited by applicant]
CN 115867546A · 2023 [cited by applicant]
CN 115872982A · 2023 [cited by applicant]
CN 113801136B · 2023 [cited by applicant]
CN 116003393A · 2023 [cited by applicant]
CN 116102543A · 2023 [cited by applicant]
CN 116102555A · 2023 [cited by applicant]
CN 116120296A · 2023 [cited by applicant]
CN 116217522A · 2023 [cited by applicant]
CN 116217558A · 2023 [cited by applicant]
CN 116323599A · 2023 [cited by applicant]
CN 116354945A · 2023 [cited by applicant]
CN 116444355A · 2023 [cited by applicant]
CN 112812077B · 2023 [cited by applicant]
CN 113816948B · 2023 [cited by applicant]
CN 113929698B · 2023 [cited by applicant]
CN 116574092A · 2023 [cited by applicant]
CN 115667222B · 2023 [cited by applicant]
CN 116804013A · 2023 [cited by applicant]
CN 116675680B · 2023 [cited by applicant]
CN 116903588A · 2023 [cited by applicant]
CN 117003748A · 2023 [cited by applicant]
CN 117003749A · 2023 [cited by applicant]
CN 117069743A · 2023 [cited by applicant]
CN 117100752A · 2023 [cited by applicant]
CN 117105932A · 2023 [cited by applicant]
CN 113773310B · 2023 [cited by applicant]
CN 117279904A · 2023 [cited by applicant]
CN 117362282A · 2024 [cited by applicant]
CN 117377666A · 2024 [cited by applicant]
CN 117417329A · 2024 [cited by applicant]
CN 117417330A · 2024 [cited by applicant]
CN 117447493A · 2024 [cited by applicant]
CN 117500789A · 2024 [cited by applicant]
CN 117500808A · 2024 [cited by applicant]
CN 117534668A · 2024 [cited by applicant]
CN 117586240A · 2024 [cited by applicant]
CN 117624145A · 2024 [cited by applicant]
CN 117897387A · 2024 [cited by applicant]
CN 117964617A · 2024 [cited by applicant]
CN 117986264A · 2024 [cited by applicant]
CN 118084936A · 2024 [cited by applicant]
CN 113493447B · 2024 [cited by applicant]
CN 118184637A · 2024 [cited by applicant]
CN 118184638A · 2024 [cited by applicant]
CN 116003403B · 2024 [cited by applicant]
CN 118271299A · 2024 [cited by applicant]
CN 118271300A · 2024 [cited by applicant]
CN 118344349A · 2024 [cited by applicant]
CN 118420603A · 2024 [cited by applicant]
CN 118496200A · 2024 [cited by applicant]
CN 2024169773A · 2024 [cited by applicant]
CN 119285580A · 2025 [cited by applicant]
CN 119306743A · 2025 [cited by applicant]
CN 119330949A · 2025 [cited by applicant]
CN 119372270A · 2025 [cited by applicant]
CN 119431365A · 2025 [cited by applicant]
CN 119431369A · 2025 [cited by applicant]
CN 119504764A · 2025 [cited by applicant]
CN 119528907A · 2025 [cited by applicant]
CN 119552158A · 2025 [cited by applicant]
JP 7461104B2 · 2024 [cited by applicant]
KR 20180101671A · 2018 [cited by applicant]
TW I495464B · 2015 [cited by applicant]
TW 201613883A · 2016 [cited by applicant]
TW I786467B · 2022 [cited by applicant]
WO 2000033839A1 · 2000 [cited by applicant]
WO 2000042026A1 · 2000 [cited by applicant]
WO 0059887A1 · 2000 [cited by applicant]
WO 2005056537A1 · 2005 [cited by applicant]
WO 2006003096A1 · 2006 [cited by applicant]
WO 2009129696A1 · 2009 [cited by applicant]
WO 2011094890A1 · 2011 [cited by applicant]
WO 2011122815A2 · 2011 [cited by applicant]
WO 2012076966A1 · 2012 [cited by applicant]
WO 2016094729A1 · 2016 [cited by applicant]
WO 2017117556A1 · 2017 [cited by applicant]
WO 2017170826A1 · 2017 [cited by applicant]
WO 2018056453A1 · 2018 [cited by applicant]
WO 2018064476A1 · 2018 [cited by applicant]
WO 2018109607A1 · 2018 [cited by applicant]
WO 2018200833A1 · 2018 [cited by applicant]
WO 2019103060A1 · 2019 [cited by applicant]
WO 2019183577A1 · 2019 [cited by applicant]
WO 2019239319A1 · 2019 [cited by applicant]
WO 2019239371A1 · 2019 [cited by applicant]
WO 2020103815A1 · 2020 [cited by applicant]
WO 2020110152A1 · 2020 [cited by applicant]
WO 2020207474A1 · 2020 [cited by applicant]
WO 2020210582A1 · 2020 [cited by applicant]
WO 2020234726A1 · 2020 [cited by applicant]
WO 2020263695A1 · 2020 [cited by applicant]
WO 2021018023A1 · 2021 [cited by applicant]
WO 2021044401A3 · 2021 [cited by applicant]
WO 2021081207A1 · 2021 [cited by applicant]
WO 2021112538A1 · 2021 [cited by applicant]
WO 2021116874A1 · 2021 [cited by applicant]
WO 2021154796A1 · 2021 [cited by applicant]
WO 2021160127A1 · 2021 [cited by applicant]
WO 2021187886A1 · 2021 [cited by applicant]
WO 2021191812A1 · 2021 [cited by applicant]
WO 2021196949A1 · 2021 [cited by applicant]
WO 2021197464A1 · 2021 [cited by applicant]
WO 2021219019A1 · 2021 [cited by applicant]
WO 2021242806A1 · 2021 [cited by applicant]
WO 2021244645A1 · 2021 [cited by applicant]
WO 2021249492A1 · 2021 [cited by applicant]
WO 2021254470A1 · 2021 [cited by applicant]
WO 2022007979A1 · 2022 [cited by applicant]
WO 2022017338A1 · 2022 [cited by applicant]
WO 2022031994A1 · 2022 [cited by applicant]
WO 2022040600A1 · 2022 [cited by applicant]
WO 2022042691A1 · 2022 [cited by applicant]
WO 2022052958A1 · 2022 [cited by applicant]
WO 2022061091A1 · 2022 [cited by applicant]
WO 2022068772A1 · 2022 [cited by applicant]
WO 2022076503A1 · 2022 [cited by applicant]
WO 2022078152A1 · 2022 [cited by applicant]
WO 2022078352A1 · 2022 [cited by applicant]
WO 2022078380A1 · 2022 [cited by applicant]
WO 2022078407A1 · 2022 [cited by applicant]
WO 2022109182A1 · 2022 [cited by applicant]
WO 2022111624A1 · 2022 [cited by applicant]
WO 2022116693A1 · 2022 [cited by applicant]
WO 2022127868A1 · 2022 [cited by applicant]
WO 2022135572A1 · 2022 [cited by applicant]
WO 2022165076A1 · 2022 [cited by applicant]
WO 2022184849A1 · 2022 [cited by applicant]
WO 2022192428A1 · 2022 [cited by applicant]
WO 2022192430A1 · 2022 [cited by applicant]
WO 2022199458A1 · 2022 [cited by applicant]
WO 2022199661A1 · 2022 [cited by applicant]
WO 2022202864A1 · 2022 [cited by applicant]
WO 2022216094A1 · 2022 [cited by applicant]
WO 2022219495A1 · 2022 [cited by applicant]
WO 2022225914A1 · 2022 [cited by applicant]
WO 2022225941A1 · 2022 [cited by applicant]
WO 2022228490A1 · 2022 [cited by applicant]
WO 2022235717A1 · 2022 [cited by applicant]
WO 2022241287A2 · 2022 [cited by applicant]
WO 2022246019A1 · 2022 [cited by applicant]
WO 2022246230A1 · 2022 [cited by applicant]
WO 2022109182A9 · 2022 [cited by applicant]
WO 2022241287A3 · 2022 [cited by applicant]
WO 2022268152A1 · 2022 [cited by applicant]
WO 2022269439A1 · 2022 [cited by applicant]
WO 2023001237A1 · 2023 [cited by applicant]
WO 2023011395A · 2023 [cited by applicant]
WO 2023011539A1 · 2023 [cited by applicant]
WO 2023016546A1 · 2023 [cited by applicant]
WO 2023025201A1 · 2023 [cited by applicant]
WO 2023029380A1 · 2023 [cited by applicant]
WO 2023031741A1 · 2023 [cited by applicant]
WO 2023049518A1 · 2023 [cited by applicant]
WO 2023051490A1 · 2023 [cited by applicant]
WO 2023057414A1 · 2023 [cited by applicant]
WO 2023057427A1 · 2023 [cited by applicant]
WO 2023057429A1 · 2023 [cited by applicant]
WO 2023076237A1 · 2023 [cited by applicant]
WO 2023098852A1 · 2023 [cited by applicant]
WO 2023106310A1 · 2023 [cited by applicant]
WO 2023111144A1 · 2023 [cited by applicant]
WO 2023111145A1 · 2023 [cited by applicant]
WO 2023116879A1 · 2023 [cited by applicant]
WO 2023116882A1 · 2023 [cited by applicant]
WO 2023124824A1 · 2023 [cited by applicant]
WO 2023125896A1 · 2023 [cited by applicant]
WO 2023130878A1 · 2023 [cited by applicant]
WO 2023138684A1 · 2023 [cited by applicant]
WO 2023151574A1 · 2023 [cited by applicant]
WO 2023151575A1 · 2023 [cited by applicant]
WO 2023152698A1 · 2023 [cited by applicant]
WO 2023164050A1 · 2023 [cited by applicant]
WO 2023164358A1 · 2023 [cited by applicant]
WO 2023169436A1 · 2023 [cited by applicant]
WO 2023169456A1 · 2023 [cited by applicant]
WO 2023179542A1 · 2023 [cited by applicant]
WO 2023182869A1 · 2023 [cited by applicant]
WO 2023191408A1 · 2023 [cited by applicant]
WO 2023198140A1 · 2023 [cited by applicant]
WO 2023220109A1 · 2023 [cited by applicant]
WO 2023220112A1 · 2023 [cited by applicant]
WO 2024018395A1 · 2024 [cited by applicant]
WO 2024026338A1 · 2024 [cited by applicant]
WO 2024028795A1 · 2024 [cited by applicant]
WO 2024041609A1 · 2024 [cited by applicant]
WO 2024046342A1 · 2024 [cited by applicant]
WO 2024051700A1 · 2024 [cited by applicant]
WO 2024051749A1 · 2024 [cited by applicant]
WO 2024063140A1 · 2024 [cited by applicant]
WO 2024063143A1 · 2024 [cited by applicant]
WO 2024102625A1 · 2024 [cited by applicant]
WO 2024107781A1 · 2024 [cited by applicant]
WO 2021155841A1 · 2024 [cited by applicant]
WO 2022048665A1 · 2024 [cited by applicant]
WO 2024125446A1 · 2024 [cited by applicant]
WO 2024125602A1 · 2024 [cited by applicant]
WO 2024129676A1 · 2024 [cited by applicant]
WO 2024131869A1 · 2024 [cited by applicant]
WO 2024137426A1 · 2024 [cited by applicant]
WO 2024138048A1 · 2024 [cited by applicant]
WO 2024148104A1 · 2024 [cited by applicant]
WO 2024149080A1 · 2024 [cited by applicant]
WO 2024153041A1 · 2024 [cited by applicant]
WO 2024153070A1 · 2024 [cited by applicant]
WO 2024160271A1 · 2024 [cited by applicant]
WO 2024169952A1 · 2024 [cited by applicant]
WO 2025002250A1 · 2025 [cited by applicant]
WO 2025002326A1 · 2025 [cited by applicant]
WO 2025006921A1 · 2025 [cited by applicant]
WO 2025007843A1 · 2025 [cited by applicant]
WO 2025021048A1 · 2025 [cited by applicant]
WO 2025026270A1 · 2025 [cited by applicant]
WO 2025026436A1 · 2025 [cited by applicant]
WO 2025045208A1 · 2025 [cited by applicant]
Pending claims in co-pending U.S. Appl. No. U.S. Appl. No. 18/884,965, entitled “GLP-1R Agonist and Therapeutic Method Thereof,” filed Sep. 13, 2024. [cited by applicant]
Analyst and Investor Call to Review Oral GLP-1 Data, The European Association for the Study of Diabetes (EASD) Annual Meeting, Stockholm, Pfizer, (2022), 1-31. [cited by applicant]
Griffith et al., A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor, J.Med. Chem., (2022), 65:8208-8226. [cited by applicant]
Zhao et al., Activation of the GLP-1 receptor by a non-peptidic agonist, Nature, (2020), 577:432-456. [cited by applicant]
Gustavson et al., TTP273, an Orally-Available Glucagon-Like Peptide-1(GLP-1)Agonist, Notably Reduces Glycemia in Subjects with Type 2 Diabetes Mellitus (T2DM), TransTech Pharma, LLC., (2014), 1-16. [cited by applicant]
Reese David, AMG 133 Program Update, AMGEN, (2022). 1-15. [cited by applicant]
Saxena et al., Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes a Randomized Clinical Trial, JAMA Network Open, (20… [cited by applicant]
Sperry et al., Danuglipron, Drugs of the Future, (2022), 47:407-418. [cited by applicant]
Pratt et al., Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, singleand multiple-ascending-dose study in healthy partici… [cited by applicant]
Zhang et al., Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists, Molecular Cell, (2020), 80:485-500. [cited by applicant]
Eccogene Announces US INDApproval for GLP-1 Receptor AgonistECC5004, Eccogene, p. 1-2, (2022). [cited by applicant]
Frias et al., Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study, Lancet, (2023), 402:472-83. [cited by applicant]
Wharton et al., Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity, N Engl J Med, 389:887-888, (2023). [cited by applicant]
Ma et al., Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist, Diabetes Ther, (2024), 15:819-832. [cited by applicant]
Stevens et al., GSBR-1290 Phase 1b Mad Results, Structure Therapeutics, (2023), p. 1-24. [cited by applicant]
Yabe, Daisuke, Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity, J Diabetes Investig, (2019), 10: 902-905. [cited by applicant]
Kawai et al., Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, PNAS, (2020), 117:29959-29967. [cited by applicant]
Clemmensen et al., Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases, Nature Reviews, Endocrinology, 15:91-104, (2019). [cited by applicant]
Pratt et al., Orforglipron (LY3502970), a novel, oral non-peptide glucagonlike peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with t… [cited by applicant]
Dutta et al., Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis, Obes Sci Pract., (2024), p. 1-9. e743. [cited by applicant]
Wu et al., Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlle… [cited by applicant]
Mao et al., Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor AgonistTing, LinStructure Therapeutics Inc, South San Francisco, CA, United States, (2023), 760-p. [cited by applicant]
Coll et al., A First-in-human Single Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1 Receptor Agonist, in Healthy Volunteers, A First-in-human Single Ascending Dose Study of GSBR-1290, a Novel Small Mole… [cited by applicant]
Kawai et al., Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, PNAS Latest Articles, (2020), p. 1-9. [cited by applicant]
Zhao et al., Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors, Nature Communications, (2022), 13:1057, p. 1-16. [cited by applicant]
Stevens et al., GSBR-1290 Obesity Topline Data Presentation, Structure therapeutics, (2024), 1-31. [cited by applicant]
Burroughs et al., TERN-601 Phase 1 Trial Top-Line Results, TERNS Pharmaceuticals, (2024), 1-29. [cited by applicant]
Hansen et al., N-terminally and C-terminally truncated forms of glucosedependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor, British Journal of Pharmacology, (2016), 1… [cited by applicant]
English Translation of WO 2025/026270 A1 (FP6). [cited by applicant]
Cited By (4)
US 12,419,874 US 12,703,700 US 12,709,614 US 12,729,200